Emergent BioSolutions plant in Baltimore begins trials of its plasma-derived therapy for COVID

Emergent BioSolutions Inc. is conducting phase clinical 3 trials of its plasma-derived therapy for outpatient treatment of COVID-19, the Maryland-based company announced. The treatment targets COVID-19 patients who are at risk of becoming severely ill.

Related Keywords

Baltimore ,Maryland ,United States ,China ,Johns Hopkins University ,National Institutes Of Health ,Chinese ,Laura Saward ,Researchers At Johns Hopkins University ,Biomedical Advanced Research ,National Institute Of Allergy ,Emergent Biosolutions Inc ,Drug Administration ,Development Authority ,Johnson ,Baltimore Sun ,Emergent Biosolutions ,East Baltimore ,President Donald Trump ,National Institute ,Infectious Disease ,National Institutes ,Anti Coronavirus Immunoglobulin , ,